Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Fruquintinib (HMPL-013) in Healthy Subjects

Next Previous
Trial Profile

A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Fruquintinib (HMPL-013) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Hutchison MediPharma

    • Most Recent Events

    • 01 Jul 2019 Results assessing pharmacokinetics profile of fruquintinib after single-dose administration in healthy subjects published in the Clinical Therapeutics
    • 24 Mar 2018 Results assessing pharmacokinetics of fruquintinib by using data from two studies including this study presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 13 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top